Tonix Pharmaceuticals Holding (TNXP) Interest Expenses (2011 - 2026)

Tonix Pharmaceuticals Holding's Interest Expenses history runs 16 years deep, the most recent figure standing at $144000.0 for Q1 2026.

• On a quarterly basis, Interest Expenses rose 23.08% year-over-year to $144000.0 in Q1 2026; TTM through Mar 2026 was $144000.0, a 67.79% decrease from a year earlier, with the FY2025 full-year figure at $6.1 million, down 90.28% from the prior year.
• Interest Expenses improved to $144000.0 in Q1 2026 per TNXP's latest filing, from -$119000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $1.8 million in Q1 2024 and bottomed at -$119000.0 in Q4 2025.
• The 5-year median for Interest Expenses is $144000.0 (2026), against an average of $478882.4.
• Across the five-year window, Interest Expenses surged 4100.0% in 2022 and plunged 270.0% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $151000.0 in 2022, then slipped by 19.21% to $122000.0 in 2023, then plunged by 42.62% to $70000.0 in 2024, then plunged by 270.0% to -$119000.0 in 2025, then jumped by 221.01% to $144000.0 in 2026.
• Per Business Quant, the three latest TNXP Interest Expenses figures stand at $144000.0 (Q1 2026), -$119000.0 (Q4 2025), and $35000.0 (Q3 2025).